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Abstract
Introduction. One of the leading causes of death in Poland is stroke. Cardiogenic stroke is known to be one of the most impor-
tant reasons for acute ischaemic stroke (AIS), comprising 25–30% of all AISs.
Aim of study. Assessment of the prevalence of different risk factors of cardiogenic causes of AIS using transthoracic echocar-
diography (TTE)
Material and methods. Transthoracic echocardiograms performed in patients with AIS admitted to a single neurological ward 
between October 2013 and September 2017 were analysed. Patients were assigned, based on the results of their TTE and their 
previous medical history of atrial fibrillation (AF), to one of three groups depending on the level of the risk of occurrence of 
cardiogenic causes of AIS. 
Ethical permission. According to Dz.U.2001, no. 126, 1381 no ethical permission was needed.
Results. 663 patients with AIS were included in the study. Patients with high risk of cardiogenic cause of AIS: 26.7% (N = 177 
patients [p]). Of these, 64.4% (114 p) were diagnosed with AF. 31.6% (56 p) with sinus rhythm during hospitalisation had a hi-
story of paroxysmal AF (PAF). In 11.9% (21 p) of the patients qualified to the high risk group, factors other than AF were found. 
Patients with moderate risk of cardiogenic cause of AIS: 10.1% (67 p).  Patients with low risk of cardiogenic cause of AIS: 25.9% 
(172 p). Echocardiographic results led to a change in therapy in 1.21% of cases.      
Conclusions. 1. Transthoracic echocardiography performed routinely in all AIS patients affects the treatment in a very low 
percentage of cases. 2. The group that could benefit the most from TTE examination includes people without established indi-
cations for chronic anticoagulant therapy, in particular patients after myocardial infarction and people with additional clinical 
symptoms. 3. In patients with AIS, the diagnostic sensitivity of TTE in the detection of PFO is low. Young people with a crypto-
genic ischaemic stroke should undergo a transoesophageal assessment.
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Introduction
Strokes are one of the leading causes of death worldwide 
[1]. It is estimated that ischaemic strokes (AIS) account for 87% 
of all strokes [2]. One of the most common causes of strokes 
is cardiogenic stroke (25–30% of all AIS) [3]. By definition, 
a cardiogenic stroke is caused by embolic material entering 
the cerebral circulation from the heart cavities. This material 
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may be thrombi formed as a result of blood flow through the 
heart, or foreign bodies present in the heart, as well as frag-
ments of tumours or bacterial vegetation. Pathologies that are 
most often associated with the formation of embolic material 
in the heart include atrial fibrillation and other conditions 
associated with the release of blood flow disturbing Virchow’s 
triad with an increased risk of thrombus formation such as 
aneurysms and post-infarction scars, degenerative valve chan-
ges, in particular in the course of rheumatic heart disease, and 
a non-compacted myocardium.
  The risk of a cardiogenic stroke can be divided into several 
groups, depending on the cause. [3, 4]. The basic examination 
by which patients can be qualified for a particular risk group 
is transthoracic echocardiography (TTE). This is recommen-
ded for every patient with a suspected cardiogenic stroke [5]. 
Potentially the greatest benefit of TTE can be experienced by 
patients in whom the detection of the source of a cardiogenic 
stroke during the examination would involve a change in 
the treatment procedure. This group includes patients with 
thrombi in the left heart cavities and patients with previously 
undiagnosed atrial fibrillation, in whom the introduction 
of an anticoagulant therapy significantly reduces the risk of 
a subsequent stroke [6]. Due to the high mortality rate, which 
is 10-17% within 14 days [7], and a high relapse rate, it is im-
portant to detect the cause of a cardiogenic stroke early and 
to implement the correct treatment.
Clinical rationale for the study
Assessment of the occurrence of cardiogenic risk factors 
for the source of acute ischaemic stroke using transthoracic 
echocardiography. 
Assessment of the effect of transthoracic echocardiograp-
hic results on treatment change.
Materials and methods
This retrospective analysis included the results of echocar-
diographic examinations carried out in consecutive patients 
hospitalised at the Neurological Ward and Stroke Ward with 
suspected AIS between October 2013 and September 2017. 
Echocardiography was performed in all patients with initially 
suspected AIS. A total of 717 studies were analysed. The tests 
were carried out using Philips Ultrasound Inc. HD11 XE 
(USA). Echocardiographic measurements and ranges of norms 
were applied in accordance with generally accepted standards 
[4]. The physician who performed the echocardiographic 
examination subjectively assessed study conditions to be 
‘normal’, ‘difficult’ or ‘very difficult’ according to the available 
acoustic window and patient cooperation leading to adequate 
visualisation of all cardiac structures. Technical difficulties 
during the examination resulted mainly from anatomical 
conditions, lack of cooperation, and difficulties in understan-
ding the process in some patients, plus related problems such 
as the patient’s optimal position for the examination. Due to 
patients’ immobilisation and the related difficulty in assessing 
biometric parameters (height and weight) that would allow 
the physician to calculate body surface, non-indexed left-
-ventricular mass (LVM) was used to assess left ventricular 
hypertrophy (standard: up to 150 g for women, up to 200 g 
for men), and for the size of the left atrium - the surface area 
in a four-chamber projection (standard: 18.9 cm2 for wo-
men; 20.3 cm2 for men) [8]. A concentric hypertrophy was 
considered when the LVM was above normal at the relative 
thickness of the left ventricle (RWT) > 0.42. The possibility 
of diagnosing hypertrophic cardiomyopathy was determined 
in accordance with current recommendations in patients with 
a thickness of the interventricular septum > 1.5 cm [9]. Dilated 
cardiomyopathy was defined as a significant enlargement of the 
left ventricular end-diastolic diameter (LVEDd) of > 6.0 cm 
coexisting with left ventricular ejection fraction (EF) < 40% 
[10]. All echocardiographic examinations were made by one 
experienced echocardiographer.
The occurrence of AF was assessed based on medical hi-
story, ECG examination descriptions, and Holter’s ECG tests 
performed during the hospitalisation.
Based on TTE results and data obtained from medical 
records, patients were assigned to one of three risk groups of 
the cardiogenic stroke source:
 — High risk group – HR
 — Moderate risk group – MR
 — Low risk group – LR
The qualification criteria were developed based on lite-
rature data. Neurologic and cardiologic (echocardiographic) 
recommendations are inconsistent [11, 12]. Some divide the 
risk of cardiogenic sources of embolic stroke into two groups 
(high and moderate) [4], while others divide it into three (high, 
moderate, and low [3]). Due to the lack of consensus on this 
subject, qualification criteria for the above-mentioned divi-
sions were combined and are presented in Table 1 [11, 13–16] 
Statistica version 13 (Statsoft) was used for statistical analysis. 
The results are presented as mean (±) standard deviations, and 
the frequency of occurrence of qualitative variables is given as 
a percentage. The analysis of variance (ANOVA) using post 
hoc Shaffe and NIR tests was used to assess the significance of 
differences between the three analysed subgroups of patients 
with current risk factors for cardiogenic stroke. The level of 
statistical significance was considered P < 0.05.
Results
The initial analysis included 717 descriptions of TTE 
research. 54 research descriptions were excluded from the 
research for the following reasons:
 — after the analysis of discharge cards, due to the lack of 
a definitive diagnosis of ischaemic stroke (49 people),
 — due to the patient’s death before a definitive diagnosis of 
ischaemic stroke (three people),
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 — due to a non-diagnostic acoustic window for echocardio-
graphy (two people).
Finally, the analysis included results of examinations of 
663 patients with AIS, including 47.8% (317) of women and 
52.2% (346) of men. The mean age of patients was 71 years 
(age range 20–97 years). A summary of the echocardiographic 
parameters is set out in Table 2.
35.3% (234 patients) of examinations were carried out 
at the bedside, 26.2% (174) under difficult conditions, and 
2.87% (19) in very difficult conditions. The most common 
abnormalities found in echocardiography were left ventricular 
hypertrophy and left atrial enlargement. 
In the studied group, 65.2% of the patients (432 patients) 
had concentric left ventricular hypertrophy. In 20.1% of the 
patients (133), the concentric hypertrophy reached values  that 
met the criteria for diagnosing hypertrophic cardiomyopathy 
based on the IVSd measurement in accordance with the re-
commendations of the European Society of Cardiology [17]. 
In 10.7% of the patients (71), eccentric hypertrophy of the left 
ventricle was found in the examination.
The incidence of enlargement of the left atrium depends 
on the used assessment method. The antero-posterior diameter 
(LAd) exceeded norms in 70.3% of the patients. Using the pla-
nimetric method (LAA - left atrial area), left atrial enlargement 
was found in 85.2% of the patients. Among this group of pa-
tients, 117 people (25.1%) were diagnosed with atrial fibrillation.
HR group
The patients with a high risk of a cardiogenic stroke source 
constituted 26.7% of all the subjects (177 people).
The mean age in the high-risk group was 77.9 years.  57.1% 
of the patients (101 people) in this group were women. The 
main factor qualifying for the HR group was the occurrence 
of atrial fibrillation (96%, 170 people). In 64.4% of the patients 
(114 people) from the HR group, atrial fibrillation occurred 
during echocardiography. 31.6% of the patients (56 people) 
with a sinus rhythm during echocardiography were qualified 
for the HR group due to paroxysmal atrial fibrillation diag-
nosed earlier or during hospitalisation.
Table 1. Risk of cardiogenic embolism depending on underlying cause
HIGH (HR) MODERATE (MR) LOW (LR)
atrial fibrillation spontaneous echo contrast in heart chambers patent foramen ovale
mechanical artificial heart valves severe or moderate degenerative changes in 
left heart valves
atrial septal aneurysm
rheumatic heart disease biological artificial heart valve prolapse of the mitral valve
thrombus in the heart chambers post-infarction left ventricular aneurysm features of post-infarction scar (without aneurysm)
infective endocarditis dilated cardiomyopathy left ventricular hypokinesia
non-compaction of the myocardium mitral annular calcification (MAC) hypertrophic cardiomyopathy
myxoma   
Table 2. Echocardiographic parameters
Low risk of cardiogenic 
stroke
Medium risk of cardio-
genic stroke
High risk of cardiogenic 
stroke
P (ANOVA)
Age (years) ± SD 70.5 ( ± 13) 78.6 (± 10) 77.9 (± 11) < 0.001 ¥*
Women (%) 37.8 50.7 57.1 < 0.001 ¥
IVSd (cm) ± SD 1.36 (±0.3) 1.34 (±0.2) 1.30 (±0.2) NS
LVED (cm) ± SD 4.83 (±0.7) 4.80 (± 0.8) 4.81 (± 0.8) NS
LV mass (g) ± SD 258 (± 89) 252 (± 102) 244 (± 88) NS
RWT ± SD 0.53 (± 0.1) 0.53 (± 0.1) 0.52 (± 0.1) NS
EF (%) ± SD 56.3 (± 8.3) 53.1 (± 12) 54.4 (± 9.9) P = 0.02*
LAd (cm) ± SD 4.16 (± 0.6) 4.21 (± 0.6) 4.56 (± 0.7) P < 0.001¥# 
LAA (cm2) ± SD 25.6 (± 5.6) 26.9 (± 8.1) 31.8 (± 7.8) P < 0.001¥# 
LAA enlargement (%) 33.7 48.8 97.3 < 0.001¥
LV enlargement (%) 12.2 16.4 14.1 NS
HCM (%) 33.7 26.9 18.6 0.001¥
EF < 35% (%) 2.3 11.9 6.2 NS
Legend: ¥P < 0.05 LR vs HR; #P < 0.05 MR vs HR; *P < 0.05 LR vs MR; IVSd – Interventricular septum thickness at end-diastole; LVED – Left ventricular end-diastolic diameter; LV mass – Left ventricle mass; RWT – 
Relative wall thickness; LAd – Antero-posterior diameter of left atrium; LAA – Left atrial area HCM – Hypertrophic cardiomyopathy; EF – Ejection fraction
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Discussion
The research that we have conducted is one of the largest 
available in the literature on the subject, and the first one 
describing the Polish population and analysing the role of an 
echocardiographic assessment in patients hospitalised due to 
acute ischaemic stroke. The echocardiographic examination 
that is often recommended and performed in patients with 
AIS seems to have little effect on further proceedings in this 
group of patients. 
During the study, only in 1.21% of all the patients did the 
TTE result influence a change in treatment. This percentage 
can be compared to the result obtained in similar research 
carried out at the Duke University Medical Centre, where the 
TTE result, subsequently confirmed by TEE, was associated 
with a change in treatment in 1.52% of patients (four people) 
[18]. The change in treatment mainly concerns patients with 
a thrombus in the heart cavity or myocardial non-compaction, 
without other indications for an anticoagulation therapy and 
patients with valvular heart diseases that require surgical 
treatment, including active IE.
Undoubtedly, the most frequent cause of formation of 
thromboembolic material in the heart cavities, which may 
become a cardiogenic stroke source, is atrial fibrillation [11]. 
AIS is the basic complication of AF that worsens the pro-
gnosis and is the cause of increased mortality in this group. 
Electrocardiographic examinations (resting, Holter) are used 
to diagnose AF. Due to the fact that all patients diagnosed 
with atrial fibrillation and AIS (25.6% of the patients in the 
research) have indications for chronic anticoagulant therapy, 
in their case the result of the echocardiographic examination 
will rarely be associated with a change in secondary prevention 
of AIS [9]. A similar conclusion can be drawn from research 
that used transoesophageal echocardiography which was 
conducted at university hospitals in Berlin on patients after an 
ischaemic stroke, both with documented AF and without such 
a diagnosis. Only 3.8% of the patients with AF were diagnosed 
with embolic material during TEE, the origin of which could 
not be explained by co-occurring atrial fibrillation. However, 
this did not change the treatment in any of these patients, and 
the echocardiographic findings had no effect on the prescrip-
tion of anticoagulants or a change in the anticoagulant therapy 
used at that time [19].
Considering the above results, performing TTE in patients 
with an ischaemic stroke and a diagnosed AF should be limited 
to people with additional disturbing symptoms such as a heart 
murmur or a fever suggestive of infective endocarditis.
Patients with AIS without any previously diagnosed atrial 
fibrillation or other indications for an anticoagulant therapy 
are a separate group. Although TTE is not a tool that allows 
a diagnosis of atrial fibrillation, it helps to distinguish tho-
se patients who are at risk of this arrhythmia.  Left atrium 
enlargement, mitral valve defects, increased left ventricular 
hypertrophy, or the presence of pulmonary hypertension 
In 11.9% of the patients (21 people) qualified for the HR 
group, non-AF factors of a high risk of a cardiogenic stroke so-
urce were detected, and in this group seven patients (four with 
an intracardiac thrombus, two with a mechanical valve, and 
one with a rheumatic defect) suffered from the co-occurrence 
of atrial fibrillation.
Finally, in 14 people (2.1% of the entire group), factors 
of a high risk of a cardiogenic stroke source other than atrial 
fibrillation were found: thrombus in left heart cavities (six 
people), presence of left-sided mechanical valve (five people), 
and one person with infective endocarditis (IE), left ventricle 
non-compaction, and a rheumatic heart defect.
MR group
The patients with a moderate risk of a cardiogenic stroke 
source constituted 10.1% of all the subjects qualified for the exa-
mination (67 people). 50.7% (34 people) of the MR group were 
women. The mean age in the moderate risk group was 78.6 years.
The most common causes qualifying for the MR group 
included: occurrence of severe degenerative changes on left-
-sided valves (52 people, 77.6%), including 34.3% (23 people) 
with mitral annulus calcification (MAC). Other causes were 
less frequent: dilated cardiomyopathy (seven people), left ven-
tricular post-infarction aneurysm and a biological valve (two 
people), spontaneous contrast in heart cavities (one person).
LR group
The patients with a low risk of a cardiogenic stroke (LR 
group) constituted 25.9% of all the subjects (172 people), of 
which women accounted for 37.8% (65 people). The mean age 
in this group was 70.5 years. One of the qualification criteria 
for this group was diagnosing persistent foramen ovale (PFO), 
which was detected in three people (0.45% of all the patients).
Other results
In 37.3% of the subjects (247 people) no potential causes 
of the cardiogenic stroke source were found. The mean age in 
the studied group was 65.3 years, and women accounted for 
47% (116 people).
A group of 10 people (1.5% of those who were included 
in the study) was identified among the patients, whose TTE 
image indicated the presence of a thrombus in the left heart 
cavities. The mean age in this group was 69.6 years, and nine 
out of 10 were men. The mean ejection fraction of patients 
with a thrombus in the heart cavity was 41%. Based on the 
echocardiographic image, previous myocardial injury was 
found in eight patients from this group. Moreover, the group 
was characterised by the presence of many comorbidities such 
as arterial hypertension (six people), cardiomyopathy (two 
people), ventricular arrhythmias (two people), renal failure 
(two), and type 2 diabetes (three people).
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found during echocardiography are all recognised risk factors 
for paroxysmal AF, which can remain subclinical for a long 
time. The first manifestation of arrhythmia is sometimes an 
ischaemic stroke [20–27]. Assessing the size of the left atrium 
seems particularly useful. In our research, enlargement of the 
left atrium assessed by the surface area (LAA) occurred in 
97.3% of the patients in the HR group, whereas enlargement 
of the left atrium assessed with the use of LAd occurred in 
83.5% of the patients in the HR group, in which people with 
AF predominated. Therefore, planimetric assessment of left 
atrium size should be preferred. Left atrial volume calculation, 
which is preferred in the guidelines, requires BSA calculation, 
which can be challenging in this population [28]. Patients 
with a significant left atrial enlargement could potentially 
benefit from prolonged electrocardiographic monitoring that 
would optimally last longer than seven days which, although 
recommended in guidelines, is still not available in Polish 
conditions [11]. 
Patients who have had a myocardial infarction and do 
not use an anticoagulation treatment are a special group that 
could benefit from echocardiographic assessment.  In our 
research, of a group of 10 patients with thrombi visible in the 
TTE, eight had traits of post-infarction myocardial injury in 
the echocardiographic examination.
Another group that can also benefit from an echocardio-
graphic examination is young patients with a cryptogenic 
stroke. In these patients, the detection of a patent persistent 
foramen ovale (PFO) with a documented right-left leak may 
be an indication for percutaneous closure to avoid recurrent 
AIS episodes [6–8, 29]. The transthoracic examination allows 
a certain diagnosis of PFO only in a minority of cases. The-
refore, in patients with suspected persistent foramen ovale, 
with a normal heart image in TTE, it is indicated to perform 
transoesophageal echocardiography (TEE) [11]. In the analy-
sed group, only 0.45% of all the subjects during the TTE had 
persistent foramen ovale. Comparing this to the population 
occurrence of PFO, which amounts to 20–28%, [30, 31] shows 
a low diagnostic sensitivity of TTE in detecting PFO, especially 
in technically difficult bedside tests. Therefore, young people 
with a real cryptogenic strokewho are potentially eligible for 
PFO closure treatment should be qualified for a transoesop-
hageal examination, which is usually made after an earlier 
transthoracic examination.
If a cardiogenic stroke source is suspected, it has been 
recommended that treatment start as early as possible to allow 
the diagnosis of a possible thrombus and to implement appro-
priate treatment as soon as possible [5]. The implementation 
of recommendations within 24 hours appears challenging. 
The limited availability of echocardiographic imaging, and 
the increasing use of echocardiographic laboratories, indicate 
a need for a careful selection of patients for this examination.
Communication between the neurologist ordering the 
treatment and the doctor performing the echocardiography is 
very important. The echocardiography order should contain 
basic information on the history of the cardiovascular sy-
stem diseases, in particular: diagnosis of atrial fibrillation, 
previous myocardial infarction, and other factors that may 
suggest rare causes of cardiogenic attacks (e.g. fever in IE). 
Information on the cryptogenic nature of AIS, in particular 
in young people, may also be important. It is also useful to 
provide a patient’s weight and height, if known, which allows 
some echocardiographic parameters to be referred to the 
patient’s body surface.
The limitations to our publication include: difficult con-
ditions of echocardiographic assessment resulting from the 
specifics of a studied group; lack of possibility to measure 
patients’ height and weight due to their severe clinical con-
ditions, and thus the lack of the possibility to scale the size 
of the heart cavities in relation to the patients’ biometric size, 
including the assessment of the volume index recommended in 
the guidelines of the left atrial size parameter. Due to the lack 
of complete data, our publication did not include the nature 
of ischaemic changes in imaging (CT MRI) and clinical scales 
of stroke severity.
Conclusions
1. Transthoracic echocardiography performed routinely in all 
AIS patients affects the treatment in a very low percentage 
of cases.
2. The group that could benefit the most from TTE exami-
nation includes people without established indications for 
chronic anticoagulant therapy, in particular patients after 
myocardial infarction and people with additional clinical 
symptoms.
3. In patients with AIS, the diagnostic sensitivity of TTE in 
the detection of PFO is low. Young people with a crypto-
genic ischaemic stroke should undergo a transoesophageal 
assessment.
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